What is the price-to-earnings ratio of Haemonetics?
The price-earnings ratio of Haemonetics is currently 37.16.
Haemonetics P/E 2024
Haemonetics P/E
37.16
Ticker
HAE
ISIN
US4050241003
WKN
881782
As of Aug 11, 2024, Haemonetics's P/E ratio was 37.16, a -3.63% change from the 38.56 P/E ratio recorded in the previous year.
The Haemonetics P/E history
Haemonetics Aktienanalyse
What does Haemonetics do?
Haemonetics Corp is a leading provider of blood processing and transfusion products. The company was founded in 1971 by Dr. Jack Latham to create a better solution for the storage and transfer of blood products. Since then, the company has become a major provider of products and services for the blood transfusion industry. Haemonetics' business model is focused on the development, manufacturing, and marketing of products and devices for blood transfusion. The company offers a wide range of products and services, including blood processing systems, blood collection and maintenance devices, software solutions, blood components, and related accessories. In recent years, Haemonetics has dedicated itself to diversifying its offerings. While still focusing on the blood transfusion industry, the company has also expanded into other areas, such as the treatment of patients with blood disorders and the development of devices for cell therapy. Haemonetics is divided into various business segments, including Blood Management Solutions, Diagnostic Solutions, and Haemonetics Software Solutions. The Blood Management Solutions segment includes a range of products, including blood collection and storage devices, centrifuges, and hematocrit systems. Diagnostic Solutions provides diagnostic tests for blood disorders, including tests for coagulation disorders and thrombophilia. Haemonetics Software Solutions offers software solutions for the blood transfusion industry, including systems for automated processing and storage of blood products, as well as systems for automatic inventory management. Haemonetics' products also include devices for freezing blood products and for processing blood components. These devices help ensure that blood products are stored at optimal temperatures and conditions to ensure their effectiveness and usability for the patient. Another important area of Haemonetics' business is the development of devices for cell therapy. The company works closely with research institutes and biotech companies to develop innovative technologies for cell therapy. This includes the development of devices for the isolation and purification of stem cells that can be used for the treatment of cancer and other diseases. Haemonetics Corp has made a name for itself in the blood transfusion industry and continues to focus on innovation and diversification to fully utilize the potential of the company and its products. With a wide range of products and services, a strong commitment to research and development, and an unwavering focus on the needs of patients and healthcare providers, Haemonetics is well positioned to continue growing and expanding in the future. Haemonetics ist eines der beliebtesten Unternehmen auf Eulerpool.com.P/E Details
Deciphering Haemonetics's P/E Ratio
The Price to Earnings (P/E) Ratio of Haemonetics is a vital metric that investors and analysts use to determine the company’s market value relative to its earnings. It is calculated by dividing the current stock price by the earnings per share (EPS). A higher P/E ratio could suggest that investors are expecting higher future growth, while a lower ratio may indicate a potentially undervalued company or lower growth expectations.
Year-to-Year Comparison
Assessing Haemonetics's P/E ratio on a yearly basis provides insights into the valuation trends and investor sentiment. An increasing P/E ratio over the years signifies growing investor confidence and expectations for future earnings growth, while a decreasing ratio may reflect concerns over the company's profitability or growth prospects.
Impact on Investments
The P/E ratio of Haemonetics is a key consideration for investors aiming to balance risk and reward. A comprehensive analysis of this ratio, in conjunction with other financial indicators, aids investors in making informed decisions regarding buying, holding, or selling the company’s stocks.
Interpreting P/E Ratio Fluctuations
Fluctuations in Haemonetics’s P/E ratio can be attributed to various factors including changes in earnings, stock price movements, and shifts in investor expectations. Understanding the underlying reasons for these fluctuations is essential for predicting future stock performance and assessing the company's intrinsic value.
Frequently Asked Questions about Haemonetics stock
How has the price-earnings ratio of Haemonetics changed compared to last year?
The price-to-earnings ratio of Haemonetics has increased by -3.63% fallen (meaning "decreased" or "dropped") compared to last year.
What consequences does a high price-earnings ratio have for investors?
A high price-to-earnings ratio indicates that the company's stock is relatively expensive and investors may potentially achieve a lower return.
What does a low price-earnings ratio mean?
A low price-earnings ratio means that the company's stock is relatively cheap and investors may potentially achieve a higher return.
Is the price-earnings ratio of Haemonetics high compared to other companies?
Yes, the price-to-earnings ratio of Haemonetics is high compared to other companies.
How does an increase in the price-earnings ratio of Haemonetics affect the company?
An increase in the price-earnings ratio of Haemonetics would lead to a higher market capitalization of the company, which in turn would lead to a higher valuation of the company.
How does a reduction in the price-to-earnings ratio of Haemonetics affect the company?
A decrease in the price-earnings ratio of Haemonetics would result in a lower market capitalization of the company, which in turn would lead to a lower valuation of the company.
What are some factors that influence the price-earnings ratio of Haemonetics?
Some factors that influence the price-earnings ratio of Haemonetics are the company's growth, financial position, industry development, and the overall economic situation.
How much dividend does Haemonetics pay?
Over the past 12 months, Haemonetics paid a dividend of . This corresponds to a dividend yield of about . For the coming 12 months, Haemonetics is expected to pay a dividend of 0 USD.
What is the dividend yield of Haemonetics?
The current dividend yield of Haemonetics is .
When does Haemonetics pay dividends?
Haemonetics pays a quarterly dividend. This is distributed in the months of .
How secure is the dividend of Haemonetics?
Haemonetics paid dividends every year for the past 0 years.
What is the dividend of Haemonetics?
For the upcoming 12 months, dividends amounting to 0 USD are expected. This corresponds to a dividend yield of 0 %.
In which sector is Haemonetics located?
Haemonetics is assigned to the 'Health' sector.
Wann musste ich die Aktien von Haemonetics kaufen, um die vorherige Dividende zu erhalten?
To receive the latest dividend of Haemonetics from 8/11/2024 amounting to 0 USD, you needed to have the stock in your portfolio before the ex-date on 8/11/2024.
When did Haemonetics pay the last dividend?
The last dividend was paid out on 8/11/2024.
What was the dividend of Haemonetics in the year 2023?
In the year 2023, Haemonetics distributed 0 USD as dividends.
In which currency does Haemonetics pay out the dividend?
The dividends of Haemonetics are distributed in USD.
Stock savings plans offer an attractive way for investors to build wealth over the long term. One of the main advantages is the so-called cost-average effect: by regularly investing a fixed amount in stocks or stock funds, you automatically buy more shares when prices are low, and fewer when they are high. This can lead to a more favorable average price per share over time. In addition, stock savings plans allow small investors access to expensive stocks, as they can participate with small amounts. Regular investment also promotes a disciplined investment strategy and helps to avoid emotional decisions, such as impulsive buying or selling. Furthermore, investors benefit from the potential appreciation of the stocks as well as from dividend distributions, which can be reinvested, enhancing the compounding effect and thus the growth of the invested capital.
Andere Kennzahlen von Haemonetics
Our stock analysis for Haemonetics Revenue stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of Haemonetics Revenue. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.
